Victoria Socha

DocwireNews

DM199, a recombinant form of endogenous human tissue kallikrein protein (KLK1), restores KLK1 levels and enables selective release of bradykinin-mediated nitric oxide, prostaglandin, and other anti-inflammatory mediators to improve renal blood flow, inflammation, oxidative stress, and fibrosis. During a presentation at the NKF Spring Clinical Meetings, Thomas Marbury, MD, and colleagues reported results of a phase 1b study designed to examine the safety, tolerability, and pharmacokinetics of DM199 in patients with diabetes and chronic kidney disease (CKD).&nbsp; The presentation was titled Open-label Study of the Pharmacokinetics , Safety, and Tolerability of DM199 in Subjects with Diabetes and Chronic Kidney Disease.The study included two cohorts of patients with type 1 or type 2 diabetes and CKD stage 3 or 4. Cohort one received a subcutaneous dose of DM 199 of 3, 5, or 8 mg/kg. Cohort two received a subcutaneous dose of DM199 3 mg/kg. The safety assessment was based on adverse events, vital signs, clinical laboratory testing, and electrocardiogram (ECG).A total of 33 patients completed the study; of those, 25 had moderate CKD and eight had severe CKD. Common adverse events were orthostatic hypotension/hypotension (30.3%), diarrhea (9.1%), injection site events (18.2%), and headache (12.15). There were no discontinuations of study drugs related to adverse events, no serious adverse events, and no changes in laboratory, blood pressure, or ECG findings observed.DM199 exhibited dose-proportional pharmacokinetics. At 24 hours, there were increases in nitric oxide (35.2%) and prostaglandin E2 (41.2%). Estimated glomerular filtration rate (eGFR) increased by 4.08 mL/min/1.73 m2 and urine albumin-to-creatinine ratio (UACR) decreased by 18.7%.In summary, the researchers said, &ldquo;DM199 was well tolerated with most adverse events at 8 mg/kg. The pharmacokinetic profile was dose-proportional and consistent with results from previous studies. DM199 single dose showed encouraging results with an increased eGFR and decreased UACR at 24 hours.&rdquo;Source: Marbury T, Alcorn H, Bakris G, et al. Open-label study of the pharmacokinetics, safety, and tolerability of DM199 in subjects with diabetes and chronic kidney disease. Abstract of a presentation at the National Kidney Foundation 2020 Spring Clinical Meetings; abstract #310.

MarkAlain Déry, DO

The Significant Danger Measles Pose for Unvaccinated Children

Infectious Disease

Andrew Moreno

Antithrombotic Care in Hemophilia: A Summary of Multi-Organizational Clinical Practice Guidance

Hemophilia

James Tumlin, MD

Joel M. Topf, MD, FACP

Proteinuria Remission With Sparsentan in FSGS

NKF Spring Clinical Meetings 2025

Latest News

Phase 1b Study of DM199 in Patients with Diabetes and CKD

Chronic Kidney Disease

DM199, a recombinant form of endogenous human tissue kallikrein protein (KLK1), restores KLK1 levels and enables selective release of bradykinin-mediated nitric oxide, ...

About Us

Editorial Policy

Advertising

Contact Us

eNewsletters

Contribute

Career Center

MashupMD

Blood Cancers Today

Cancer Nursing Today

GU Oncology Now

Urban Health Today

Bile Duct Cancer

Colorectal Cancer

Gastroesophageal Cancer

Gastric Cancer

GEP-NETs

GIST

Liver Cancer

Pancreatic Cancer

GI Oncology Now

Anemia

Deep Vein Thrombosis

Essential Thrombocythemia

Immune Thrombocytopenic Purpura

Myelodysplastic Syndromes

Myelofibrosis

Myeloproliferative Neoplasms

Polycythemia Vera

Pulmonary Embolism

Sickle Cell Disease

Thrombocytopenia

Thrombophilia

Thrombosis

Thrombotic Thrombocytopenic Purpura

Venous Thromboembolism

von Willebrand Disease

Heme Today

Acute Kidney Injury

ADPKD

Anemia and Kidney Disease

COVID-19 and Kidney Disease

Diabetes and Hypertension

End-Stage Renal Disease

Gout

Hyperkalemia

IgAN

Kidney Transplantation

Metabolic Acidosis

Nephrology Times

HER2 Breast Cancer

HR Breast Cancer

Triple-Negative Breast Cancer

Genetics & Breast Cancer

Breast Cancers Today

Atherosclerotic Disease

Atrial Fibrillation

Heart Failure

Hypertension

Interventional Cardiology

Lipid Management

Practice Tips With Dr. Lichaa

Preventive Cardiology

Stroke

Cardiology

Breast Cancer

Gynecologic Cancer

Head and Neck Cancer

Skin Cancer

Oncology

Sleep

Urology

Diabetes

Ophthalmology

— Demodex Blepharitis

Neurology

Rheumatology

Gastroenterology

Pulmonology

Infectious Diseases

— HIV

Health and Wellness

Lupus

Future of Medicine

Orthopedics

Pharmacology

Career News

More

Conferences

CardioNerds

The Sleep Source With Dr. Morse

Rheumatology Rounds With Dr. Maheswaranathan

Partners

Expert Interviews

Subscribe